» Articles » PMID: 37436471

Characteristics and Outcomes of COVID-19 in Patients with Plasma Cell Dyscrasias During the First Omicron Wave in Beijing Since December 2022: a Retrospective Study at a National Clinical Research Center for Hematologic Disease

Overview
Journal Ann Hematol
Specialty Hematology
Date 2023 Jul 12
PMID 37436471
Authors
Affiliations
Soon will be listed here.
Abstract

The wave of coronavirus disease 2019 (COVID-19) with Omicron variant reached its first peak in Beijing, China in December 2022. We delineated characteristics and factors associated with adverse outcome of patients with plasma cell dyscrasias (PCDs) and COVID-19 during the first month of the wave. A total of 104 patients with a median age of 65 years were included in the study, with multiple myeloma (74%, n=77) and primary Immunoglobulin light chain amyloidosis (16.3%, n=17) being the two most common disease. Overall, severe or critical COVID-19 was developed in 18 (17.3%) patients, with a total all-cause mortality rate of 4.8% (n=5). The vaccination coverage was 41% and 48.1%, before and during the upsurge of Omicron, respectively, calling for the improvement of vaccination in PCD patients. Multivariable analysis revealed that age was the only independent risk factors (OR=1.14, 95% CI: 1.06-1.26, p = 0.002) associated with the development of severe or critical disease. Among patients with severe or critical group, low levels of albumin (HR=18.29; 95% CI: 1.82-183.44, p = 0.013) and high levels of lactic dehydrogenase (LDH) (HR=0.08; 95% CI: 0.01-0.65, p = 0.018) were associated with longer time to negative conversion of COVID-19.

Citing Articles

Clinical characteristics and outcomes of BCMA-targeted CAR-T cell recipients with COVID-19 during the Omicron wave: a retrospective study.

Zheng H, Han S, Chen Y, Zhao H, Chen R, Zhang Q Bone Marrow Transplant. 2025; .

PMID: 39984750 DOI: 10.1038/s41409-025-02525-1.

References
1.
Terpos E, Engelhardt M, Cook G, Gay F, Mateos M, Ntanasis-Stathopoulos I . Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020; 34(8):2000-2011. PMC: 7244257. DOI: 10.1038/s41375-020-0876-z. View

2.
Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M . COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol. 2021; 8(12):e934-e946. PMC: 8553271. DOI: 10.1016/S2352-3026(21)00278-7. View

3.
Langerbeins P, Hallek M . COVID-19 in patients with hematologic malignancy. Blood. 2022; 140(3):236-252. PMC: 9098396. DOI: 10.1182/blood.2021012251. View

4.
Pagano L, Salmanton-Garcia J, Marchesi F, Busca A, Corradini P, Hoenigl M . COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021; 14(1):168. PMC: 8515781. DOI: 10.1186/s13045-021-01177-0. View

5.
Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P . Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. Blood. 2022; 139(9):1409-1412. PMC: 8736278. DOI: 10.1182/blood.2021014989. View